Product Description
Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)
Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Premier Inc
Company Location:
Company CEO:
Additional Commercial Interests: Pfizer
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Retinoblastoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma
Phase 2: COVID-19|Desmoplastic Small Round Cell Tumor|Fetal Diseases|Follicular Lymphoma|Lymphoproliferative Disorders|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Small Cell Sarcoma|T-Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
59% |
2024-11-27 |
|
| 2018-003335-29 | P3 |
Active, not recruiting |
Other |
2029-10-15 |
2022-03-13 |
Treatments |
|
| REFRACT | P2 |
Recruiting |
Follicular Lymphoma |
2029-05-31 |
78% |
2024-11-27 |
|
| NCT06709495 | P2 |
Recruiting |
Desmoplastic Small Round Cell Tumor|Primitive Neuroectodermal Tumors|Osteosarcoma|Sarcoma, Ewing|Rhabdomyosarcoma|Small Cell Sarcoma|Peripheral Neuroectodermal Tumors, Primitive |
2028-11-01 |
12% |
2025-02-14 |
|
| RG1124788 | P2 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia |
2027-12-31 |
12% |
2024-12-19 |
Primary Endpoints|Treatments |
| LBL 2018 | P3 |
Recruiting |
Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2027-11-22 |
2024-11-27 |
||
| AAAV2404 | P2 |
Recruiting |
Lymphoproliferative Disorders|Lymphoma, B-Cell |
2027-04-14 |
2025-05-03 |
Primary Endpoints|Treatments |
|
| TOT17 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-09-30 |
27% |
2024-11-27 |
Primary Endpoints|Treatments |
| EuroNet-PHL-C2 | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2026-09-30 |
2021-05-14 |
Primary Endpoints|Treatments|Trial Status |
|
| CIBI308Y047 | P2 |
Not yet recruiting |
Diffuse Large B-Cell Lymphoma |
2025-12-31 |
54% |
2024-11-27 |
Primary Endpoints|Treatments |
| SBSDS | P2 |
Not yet recruiting |
Pregnancy Complications, Infectious|COVID-19|Pregnancy Outcomes|Fetal Diseases |
2022-12-31 |
|||
| SWIFT 02 | P3 |
Not yet recruiting |
T-Cell Peripheral Lymphoma |
2031-12-01 |
55% |
2025-04-30 |
Primary Endpoints|Treatments |
| 2019-004153-93 | P3 |
Active, not recruiting |
Sarcoma, Ewing |
2030-12-17 |
2025-05-31 |
Treatments |
|
| GOLSEEK-1 | P3 |
Recruiting |
Lymphoma, B-Cell |
2028-08-14 |
75% |
2024-11-27 |
|
| AIEOP-BFM ALL 2017 | P3 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2028-07-14 |
2024-11-27 |
Primary Endpoints |
|
| SJALL23H | P2 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2028-05-01 |
12% |
2025-01-11 |
|
| ALLTogether1 | P3 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2027-06-30 |
12% |
2024-11-27 |
|
| cHOD17 | P2 |
Recruiting |
Hodgkin Lymphoma |
2027-01-01 |
12% |
2024-11-27 |
Primary Endpoints |
| NCT03020030 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-11-30 |
38% |
2025-01-04 |
|
| CSPC-DED-DLBCL-K15 | P2 |
Not yet recruiting |
Diffuse Large B-Cell Lymphoma |
2026-02-01 |
12% |
2025-04-11 |
Primary Endpoints|Treatments |
| NP40126 | P1 |
Completed |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2024-12-02 |
41% |
2025-01-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| GO43075 | P2 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma |
2024-10-24 |
12% |
2025-05-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| B-NHL 2013 | P3 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2024-08-01 |
2025-03-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| IntReALL SR 2010 | P3 |
Completed |
Acute Lymphoid Leukemia |
2024-04-25 |
2025-05-06 |
Treatments |